Cargando…
Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems
Epigenetic aberrations are prominent in bladder cancer (BC) and contribute to disease pathogenesis. We characterized histone deacetylase (HDAC) expression, a family of deacetylation enzymes, in both in vitro and in vivo BC model systems and analyzed expression data from The Cancer Genome Atlas (TCGA...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567299/ https://www.ncbi.nlm.nih.gov/pubmed/31137849 http://dx.doi.org/10.3390/ijms20102599 |
_version_ | 1783427045047402496 |
---|---|
author | Buckwalter, Jenna M. Chan, Wilson Shuman, Lauren Wildermuth, Thomas Ellis-Mohl, Justine Walter, Vonn Warrick, Joshua I. Wu, Xue-Ru Kaag, Matt Raman, Jay D. DeGraff, David J. |
author_facet | Buckwalter, Jenna M. Chan, Wilson Shuman, Lauren Wildermuth, Thomas Ellis-Mohl, Justine Walter, Vonn Warrick, Joshua I. Wu, Xue-Ru Kaag, Matt Raman, Jay D. DeGraff, David J. |
author_sort | Buckwalter, Jenna M. |
collection | PubMed |
description | Epigenetic aberrations are prominent in bladder cancer (BC) and contribute to disease pathogenesis. We characterized histone deacetylase (HDAC) expression, a family of deacetylation enzymes, in both in vitro and in vivo BC model systems and analyzed expression data from The Cancer Genome Atlas (TCGA). Quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting analysis was used to determine the expression status of Class I and II HDACs in ten human BC cell lines, while qRT-PCR was used to determine HDAC expression in 24 human tumor specimens. The TCGA cohort consists of 408 muscle invasive BC (MIBC) clinical samples and analysis of this data set identified expression of HDAC4 and -9 as being associated with basal–squamous disease. These findings agree with qRT-PCR results identifying increased expression of HDAC4, -7, and -9 in basal BC cell lines (p < 0.05; Kruskal–Wallis test) and in clinical specimens with invasive bladder cancer (not statistically significant). We also observed increased expression in Hdac4, -7, and -9 in commonly used BC mouse models. Here, we identify suitable preclinical model systems for the study of HDACs, and show increased expression of Class IIa HDACs, specifically HDAC4 and HDAC9, in basal BC cell lines and in invasive clinical specimens. These results suggest this class of HDACs may be best suited for targeted inhibition in patients with basal BC. |
format | Online Article Text |
id | pubmed-6567299 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65672992019-06-17 Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems Buckwalter, Jenna M. Chan, Wilson Shuman, Lauren Wildermuth, Thomas Ellis-Mohl, Justine Walter, Vonn Warrick, Joshua I. Wu, Xue-Ru Kaag, Matt Raman, Jay D. DeGraff, David J. Int J Mol Sci Article Epigenetic aberrations are prominent in bladder cancer (BC) and contribute to disease pathogenesis. We characterized histone deacetylase (HDAC) expression, a family of deacetylation enzymes, in both in vitro and in vivo BC model systems and analyzed expression data from The Cancer Genome Atlas (TCGA). Quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting analysis was used to determine the expression status of Class I and II HDACs in ten human BC cell lines, while qRT-PCR was used to determine HDAC expression in 24 human tumor specimens. The TCGA cohort consists of 408 muscle invasive BC (MIBC) clinical samples and analysis of this data set identified expression of HDAC4 and -9 as being associated with basal–squamous disease. These findings agree with qRT-PCR results identifying increased expression of HDAC4, -7, and -9 in basal BC cell lines (p < 0.05; Kruskal–Wallis test) and in clinical specimens with invasive bladder cancer (not statistically significant). We also observed increased expression in Hdac4, -7, and -9 in commonly used BC mouse models. Here, we identify suitable preclinical model systems for the study of HDACs, and show increased expression of Class IIa HDACs, specifically HDAC4 and HDAC9, in basal BC cell lines and in invasive clinical specimens. These results suggest this class of HDACs may be best suited for targeted inhibition in patients with basal BC. MDPI 2019-05-27 /pmc/articles/PMC6567299/ /pubmed/31137849 http://dx.doi.org/10.3390/ijms20102599 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Buckwalter, Jenna M. Chan, Wilson Shuman, Lauren Wildermuth, Thomas Ellis-Mohl, Justine Walter, Vonn Warrick, Joshua I. Wu, Xue-Ru Kaag, Matt Raman, Jay D. DeGraff, David J. Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems |
title | Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems |
title_full | Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems |
title_fullStr | Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems |
title_full_unstemmed | Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems |
title_short | Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems |
title_sort | characterization of histone deacetylase expression within in vitro and in vivo bladder cancer model systems |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567299/ https://www.ncbi.nlm.nih.gov/pubmed/31137849 http://dx.doi.org/10.3390/ijms20102599 |
work_keys_str_mv | AT buckwalterjennam characterizationofhistonedeacetylaseexpressionwithininvitroandinvivobladdercancermodelsystems AT chanwilson characterizationofhistonedeacetylaseexpressionwithininvitroandinvivobladdercancermodelsystems AT shumanlauren characterizationofhistonedeacetylaseexpressionwithininvitroandinvivobladdercancermodelsystems AT wildermuththomas characterizationofhistonedeacetylaseexpressionwithininvitroandinvivobladdercancermodelsystems AT ellismohljustine characterizationofhistonedeacetylaseexpressionwithininvitroandinvivobladdercancermodelsystems AT waltervonn characterizationofhistonedeacetylaseexpressionwithininvitroandinvivobladdercancermodelsystems AT warrickjoshuai characterizationofhistonedeacetylaseexpressionwithininvitroandinvivobladdercancermodelsystems AT wuxueru characterizationofhistonedeacetylaseexpressionwithininvitroandinvivobladdercancermodelsystems AT kaagmatt characterizationofhistonedeacetylaseexpressionwithininvitroandinvivobladdercancermodelsystems AT ramanjayd characterizationofhistonedeacetylaseexpressionwithininvitroandinvivobladdercancermodelsystems AT degraffdavidj characterizationofhistonedeacetylaseexpressionwithininvitroandinvivobladdercancermodelsystems |